Directory
Xavier Matias-Guiu Guia

Xavier Matias-Guiu Guia

Degree: PhD

973 705 340
fjmatiasguiu.lleida.ics(ELIMINAR)@gencat.cat

ResearcherID: http://www.researcherid.com/rid/C-3039-2009

Publications

  • Concin N; Creutzberg CL; Vergote I; Cibula D; Mirza MR; Marnitz S; Ledermann JA; Bosse T; Chargari C; Fagotti A; Fotopoulou C; González-Martín A; Lax SF; Lorusso D; Marth C; Morice P; Nout RA; O'Donnell DE; Querleu D; Raspollini MR; Sehouli J; Sturdza AE; Taylor A; Westermann AM; Wimberger P; Colombo N; Planchamp F; Matias-Guiu X

    ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma.

    VIRCHOWS ARCHIV 478 153-190. .

    [doi:10.1007/s00428-020-03007-z]

  • Concin N; Matias-Guiu X; Vergote I; Cibula D; Mirza MR; Marnitz S; Ledermann J; Bosse T; Chargari C; Fagotti A; Fotopoulou C; Gonzalez Martin A; Lax S; Lorusso D; Marth C; Morice P; Nout RA; O'Donnell D; Querleu D; Raspollini MR; Sehouli J; Sturdza A; Taylor A; Westermann A; Wimberger P; Colombo N; Planchamp F; Creutzberg CL

    ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma.

    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 31 12-39. .

    [doi:10.1136/ijgc-2020-002230]

  • MATIAS-GUIU GUIA, XAVIER

    Endometrial Cancer Histopathology Reporting Guide

    Endometrial Cancer Histopathology Reporting Guide -. .

  • Romero I; Rubio MJ; Medina M; Matias-Guiu X; Santacana M; Schoenenberger JA; Guerra EM; Cortés A; Minig L; Coronado P; Cueva JF; Gómez L; Malfettone A; Sampayo M; Llombart-Cussac A; Poveda A

    An olaparib window-of-opportunity trial in patients with early-stage endometrial carcinoma: POLEN study.

    GYNECOLOGIC ONCOLOGY 159 721-731. .

    [doi:10.1016/j.ygyno.2020.09.013]

  • Miller RE; Leary A; Scott CL; Serra V; Lord CJ; Bowtell D; Chang DK; Garsed DW; Jonkers J; Ledermann JA; Nik-Zainal S; Ray-Coquard I; Shah SP; Matias-Guiu X; Swisher EM; Yates LR

    ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.

    ANNALS OF ONCOLOGY 31 1606-1622. .

    [doi:10.1016/j.annonc.2020.08.2102]

  • Mellid S; Coloma J; Calsina B; Monteagudo M; Roldán-Romero JM; Santos M; Leandro-García LJ; Lanillos J; Martínez-Montes ÁM; Rodríguez-Antona C; Montero-Conde C; Martínez-López J; Ayala R; Matias-Guiu X; Robledo M; Cascón A

    Novel DNMT3A Germline Variant in a Patient with Multiple Paragangliomas and Papillary Thyroid Carcinoma.

    Cancers 12 1-12. .

    [doi:10.3390/cancers12113304]

  • Rodriguez-Hernandez I; Maiques O; Kohlhammer L; Cantelli G; Perdrix-Rosell A; Monger J; Fanshawe B; Bridgeman VL; Karagiannis SN; Penin RM; Marcolval J; Marti RM; Matias-Guiu X; Fruhwirth GO; Orgaz JL; Malanchi I; Sanz-Moreno V

    WNT11-FZD7-DAAM1 signalling supports tumour initiating abilities and melanoma amoeboid invasion.

    Nature Communications 11 5315-5315. .

    [doi:10.1038/s41467-020-18951-2]

  • Cuatrecasas M; Gorostiaga I; Riera C; Saperas E; Llort G; Costa I; Matias-Guiu X; Carrato C; Navarro M; Pineda M; Dueñas N; Brunet J; Marco V; Trias I; Busteros JI; Mateu G; Balaguer F; Fernández-Figueras MT; Esteller M; Musulén E

    Complete Loss of EPCAM Immunoexpression Identifies EPCAM Deletion Carriers in MSH2-Negative Colorectal Neoplasia.

    Cancers 12 1-20. .

    [doi:10.3390/cancers12102803]

  • Megino-Luque C; Moiola CP; Molins-Escuder C; López-Gil C; Gil-Moreno A; Matias-Guiu X; Colas E; Eritja N

    Small-Molecule Inhibitors (SMIs) as an Effective Therapeutic Strategy for Endometrial Cancer.

    Cancers 12 1-26. .

    [doi:10.3390/cancers12102751]

  • Da Cruz Paula A; da Silva, EM; Segura, SE; Pareja, F; Bi, R; Selenica, P; Kim, SH; Ferrando, L; Vahdatinia, M; Soslow, RA; Vidal, A; Gatius, S; Przybycin, CG; Abu-Rustum, NR; Matias-Guiu, X; Rubin, BP; Reis, JS; DeLair, DF; Weigelt, B

    Genomic profiling of primary and recurrent adult granulosa cell tumors of the ovary.

    Modern Pathology 33 1606-1617. .

    [doi:10.1038/s41379-020-0514-3]

  • Damaso, E; Gonzalez-Acosta, M; Vargas-Parra, G; Navarro, M; Balmaña J; Ramon Y Cajal T; Tuset, N; Thompson, BA; Marin, F; Fernandez, A; Gomez, C; Velasco À; Solanes, A; Iglesias, S; Urgel, G; Lopez, C; del Valle, J; Campos, O; Santacana, M; Matias-Guiu, X; Lazaro, C; Valle, L; Brunet, J; Pineda, M; Capella, G

    Comprehensive Constitutional Genetic and Epigenetic Characterization of Lynch-Like Individuals.

    Cancers 12 1-32. .

    [doi:10.3390/cancers12071799]

  • Mayo-de-las-Casas, C; Velasco, A; Sanchez, D; Martínez-Bueno A; Garzón-Ibáñez M; Gatius, S; Ruiz-Mir?, M; Gonzalez-Tallada, X; Llordella, I; Tresserra, F; Rodríguez S; Aldeguer, E; Roman-Canal, B; Bertran-Alamillo, J; García-Peláez B; Rosell, R; Molina-Vila, MA; Matias-Guiu, X

    Detection of somatic mutations in peritoneal lavages and plasma of endometrial cancer patients: a proof-of-concept study.

    INTERNATIONAL JOURNAL OF CANCER 147 277-284. .

    [doi:10.1002/ijc.32872]

Projects

  • Homologous recombination deficiency in high-grade endometrial cancers. Biomarkers and impact of intratumor heterogeneity.
  • EPH Receptor Signaling in Endometrial Cancer
  • Ajuts per a la contractació de personal investigador novell (FI)
  • Personalized Immunotherapy for Endometrial Cancer; Acronym: ExCITE (Endometrial Cancer Immunotherapy)
  • "Multi-Omics data for Cancer Research and the Development of New Diagnostics and Therapies"
  • EFFICACY: Nuevas estrategias para incrementar efectividad de los tratamientos con ABTL0812
  • Incorporación de nuevas areas temáticas y nuevos grupos al consorcio CIBER
  • Perfiles epigenéticos asociados a patrones de metastasis en cáncer de endometrio
  • CONTRACTES D'INCORPORACIO DE CIENTIFICS I TECNOLEGS: INCORPORACIO D'UNA DOCTORA PER A L'ACCIO ANTITUMORAL DELS CANNABINOIDES EN EL CARCINOMA D'ENDOMETRI
  • DISCOVERY, VALIDATION AND IMPLEMENTATION OF BIOMARKERS FOR PRECISION ONCOLOGY
  • Desarrollo de nuevas aproximaciones en el manejo individualizado de pacientes con cancer ginecológico (PREDICTGYN)
  • VALIDACION DE ANEXINA 2 COMO PREDICTOR DE RECIDIVA EN EL CANCER DE ENDOMETRIO. DISEÑO DE NUEVAS ESTRATEGIAS TERAPEUTICAS. ANXARECU